<DOC>
	<DOCNO>NCT01631097</DOCNO>
	<brief_summary>This Phase 1 , open-label , single dose study design evaluate pharmacokinetics , safety tolerability single 1.5 mg tivozanib dose subject vary degree hepatic impairment normal hepatic function .</brief_summary>
	<brief_title>A Single-Dose Study Tivozanib Subjects With Hepatic Impairment Normal Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>BMI 18 38 kg/m2 diagnosis chronic stable hepatic insufficiency , ChildPugh classification score mild , moderate severe . Current previous history hepatic carcinoma , hepatorenal syndrome , portacaval shunt surgery , significant hepatic encephalopathy , severe ascites , pleural effusion Currently undergo dialysis Poor peripheral venous access Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>